Abstract
Neurodegenerative diseases termed Tauopathies, including Alzheimer disease, are characterized by the presence of intraneuronal neurofibrillary tangles (NFTs), composed by hyperphosphorylated protein Tau. Peptidyl-prolyl cis/trans isomerase Pin1 plays a pivotal role in the regulation of Tau phosphorylation/dephosphorylation state. Indeed, Pin1 specifically recognizes pThr231-Pro232 motif of Tau, catalyzes its isomerisation and, in dependence of the cellular environment, promotes its dephosphorylation by PP2A phosphatase: in the dephosphorylated state Tau is able to exert its physiological activity, promoting microtubules polymerization. However, Pin1 activity in Tauopathies in which Tau is mutated can be harmful, because the isomerase can accelerate progression of the disease. Taking into account the complexity of pathways in which Pin1, under a strict regulation, exerts its biological functions, this isomerase can be consider a promising target in the improvement and design of new therapies against Tauopathies.
Keywords: <, Tau protein, conformation, Pin1 enzyme, role in Alzheimer's disease, pathogenic onset of AD, TauSer262, neurodegeneration, pSer/Thr-Pro, peptidyl-prolyl, Pin1, mediated-transcriptional regulation, Thr668-Pro, MARK
Current Alzheimer Research
Title: Pin1: A New Outlook in Alzheimers Disease
Volume: 8 Issue: 6
Author(s): E. Lonati, M. Masserini and A. Bulbarelli
Affiliation:
Keywords: <, Tau protein, conformation, Pin1 enzyme, role in Alzheimer's disease, pathogenic onset of AD, TauSer262, neurodegeneration, pSer/Thr-Pro, peptidyl-prolyl, Pin1, mediated-transcriptional regulation, Thr668-Pro, MARK
Abstract: Neurodegenerative diseases termed Tauopathies, including Alzheimer disease, are characterized by the presence of intraneuronal neurofibrillary tangles (NFTs), composed by hyperphosphorylated protein Tau. Peptidyl-prolyl cis/trans isomerase Pin1 plays a pivotal role in the regulation of Tau phosphorylation/dephosphorylation state. Indeed, Pin1 specifically recognizes pThr231-Pro232 motif of Tau, catalyzes its isomerisation and, in dependence of the cellular environment, promotes its dephosphorylation by PP2A phosphatase: in the dephosphorylated state Tau is able to exert its physiological activity, promoting microtubules polymerization. However, Pin1 activity in Tauopathies in which Tau is mutated can be harmful, because the isomerase can accelerate progression of the disease. Taking into account the complexity of pathways in which Pin1, under a strict regulation, exerts its biological functions, this isomerase can be consider a promising target in the improvement and design of new therapies against Tauopathies.
Export Options
About this article
Cite this article as:
Lonati E., Masserini M. and Bulbarelli A., Pin1: A New Outlook in Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717140
DOI https://dx.doi.org/10.2174/156720511796717140 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy A TRIBUTE TO A LIVING LEGEND (Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman.)
Combinatorial Chemistry & High Throughput Screening Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Current Pharmaceutical Design New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) Gene Therapy for Wiskott-Aldrich Syndrome
Current Gene Therapy Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry The Current Chemical Utility of Marine and Terrestrial Filamentous Fungi in Side-Chain Chemistry
Current Organic Chemistry Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Current Drug Targets Synthesis and Anticancer Activity of Some 1H-inden-1-one Substituted (Heteroaryl)Acetamide Derivatives
Letters in Drug Design & Discovery Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy